尼尔西维玛和RSV支气管炎的住院治疗
Zein Assad1, Anne-Sophie Romain1, Camille Aupiais1
1From the Department of General Pediatrics, Pediatric Infectious Disease, and Internal Medicine (Z.A., A.G., N.O.), Centre d'Investigations Cliniques, INSERM Unité 1426 (Z.V.), the Pediatric Intensive Care Unit (M. Levy, P.S.), the Pediatric Emergency Department (L.L.), the Department of Microbiology (M.G.-M.), the Neonatal Intensive Care Unit (V.B.), and the Unit of Clinical Epidemiology, INSERM Unité 1123 and Epidémiologie Clinique du Centre d'Investigation Clinique 1426 (K.D., O.A.), Robert-Debré University Hospital, Paris Cité University (Z.A., C.S., A.G., Z.V., M.B., J.F.C., J.T., M.L., P.S., L.L., M.G.-M., V.B., K.D., O.A.), the Departments of General Pediatrics (A.-S.R., M. Lorrot, C.F.) and Pediatric Pulmonology (A.-S.R., M. Lorrot), Armand Trousseau University Hospital, Sorbonne University (A.-S.R., M. Lorrot), the Pediatric Emergency Department (C.S.), the Pediatric Intensive Care Unit (M.B.), and the Department of General Pediatrics and Pediatric Infectious Diseases (C.S., J.F.C., J.T.), Necker-Enfants Malades University Hospital, Saint-Antoine Research Center, INSERM Unité Mixte de Recherche (UMR) S938 (H.C., B.P.), and Assistance Publique-Hôpitaux de Paris (AP-HP), Infection, Antimicrobials, Modeling, and Evolution (IAME) Research Unit, INSERM UMR 1137 (Z.A., L.L., M.G.-M., N.O.), Épidémiologie Clinique et Évaluation Économique Appliqué aux Populations Vulnérables, INSERM UMR 1123 (C.A.), the Center of Research in Epidemiology and Statistics, INSERM UMR 1153 (J.F.C.), and Biodiversity and Epidemiology of Bacterial Pathogens Research Unit, Institut Pasteur (J.T.), Paris Cité University, Paris, Groupe de Pathologie Infectieuse Pédiatrique, Nice (Z.A., M. Lorrot, R.C., C.L., N.O.), the Pediatric Emergency Department (C.A.) and the Department of General Pediatrics (L.P., C.F.D.), Jean Verdier University Hospital, AP-HP de Paris, Bondy, the Department of General Pediatrics, Centre Hospitalier Intercommunal de Créteil (M.S., C.J.), Association Clinique et Thérapeutique Infantile du Val-de-Marne France (R.C., C.L.), Institut Mondor de Recherche Biomédicale-Groupe de Recherche Clinique Groupe d'Étude des Maladies Infectieuses Néonatales et Infantiles, Université Paris Est (R.C., C.L., C.J.), and the Clinical Research Center (M.M.E.H., C.J.) and the Neonatal Intensive Care Unit (X.D.), Centre Hospitalier Intercommunal de Créteil, Université Paris Est Créteil, Faculté de Santé de Créteil, Créteil, Association Française de Pédiatrie Ambulatoire, Orleans (R.C., C.L.), and the Departments of Pediatric Pulmonology and Allergology (G.L., N.C.) and General Pediatrics (B.H., O.M., C.B.), Children's Hospital, Toulouse University Hospital, Toulouse - all in France; and the Department of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (F.A.).
尼尔西维玛能有效地减少婴儿因呼吸道综合体病毒 (RSV) 相关的支气管炎住院. 这项实践研究表明,尼尔塞维马布治疗显著降低了幼儿严重RSV疾病的风险.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 呼吸道综合体病毒 (RSV) 是婴儿支气管炎的主要原因,每年导致全球数百万人住院治疗.
- 长效单克隆抗体Nirsevimab针对RSV,但其在许可后的实际有效性需要评估.
研究的目的:
- 评估nirsevimab在预防12个月以下婴儿因RSV相关支气管炎住院治疗中的实际有效性.
- 分析nirsevimab对重症结局的影响,如重症监护和呼吸系统支持.
主要方法:
- 进行了一项前性,多中心,匹配的病例控制研究.
- 由于RSV支气管炎住院的婴儿 (病例) 与因其他疾病住院的婴儿 (对照组) 根据年龄,访问日期和研究中心相匹配,比率为2:1.
- 使用多变量条件逻辑回归来计算nirsevimab的有效性,并对混因素进行调整.
主要成果:
- 这项研究包括1035名婴儿 (690例,345例对照).
- 尼尔塞维马布治疗显示,针对RSV相关的支气管炎住院治疗的调整后有效率为83.0% (95% CI,73.4-89.2).
- 针对重症监护和呼吸器支持的有效性分别为69.6% (95% CI,42.9-83.8) 和67.2% (95% CI,38.6-82.5).
结论:
- 在现实环境中,nirsevimab疗法有效降低婴儿RSV相关支气管炎住院的风险.
- 这些发现支持nirsevimab在保护幼儿免受严重RSV疾病方面的作用.
更多相关视频
相关概念视频
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-III
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...


